US/UK/Canada

Share

Quotes

The animal models we develop focus on disorders and diseases that manifest as dysregulation within neuronal networks, which is probably the most challenging aspect to simulate successfully. However, we can model the effects of the drugs we identify on specific genetic targets, enabling us to obtain critical information and significantly reduce the risk of failure going forward.
Dr. Karl Æ. Karlsson
Pick a time period -
Tags ( Active)

3Z Pharmaceuticals Publishes Breakthrough Study on Shared Metabolic Pathways in ADHD Therapeutics

REYKJAVIK, Iceland, 24 February 2025 – 3Z Pharmaceuticals, a CNS-focused therapeutic development specialist, today announced the publication of a groundbreaking study  in The Journal of Pharmacology and Experimental Therapeutics, unveiling novel insights into the metabolic mechanisms of ADHD treatments. This research, utilizing untargeted metabolomic and lipidomic profiling, addresses a critical knowledge gap in ADHD treatment. It reveals a convergence of molecular pathways among stimulant and non-stimulant ADHD

3Z Pharmaceuticals Unveils Landmark Study Supporting Calcium Channel Blocker as a Groundbreaking ADHD Therapy

3Z Pharmaceuticals Unveils Landmark Study Supporting Calcium Channel Blocker as a Groundbreaking ADHD Therapy REYKJAVIK, Iceland, 17.02.2025 3Z Pharmaceuticals today announced the publication of a transformative study in Neuropsychopharmacology, highlighting compelling scientific evidence that positions the mechanisms engaged by amlodipine, an L-type calcium channel  blocker (LTCC), as a foundation for a novel therapy for ADHD. The findings provide robust validation of 3Z’s cutting-edge high-throughput drug discovery platform and introduce new avenues for non-stimulant-based ADHD

3Z and biotx.ai Forge Partnership to Advance ADHD Drug Development Using AI Modelling

Reykjavik-based drug discovery company, 3Z, and Germany/US-based causal AI firm, biotx.ai, have joined forces in a strategic partnership aimed at revolutionizing ADHD drug development. By leveraging advanced AI modelling techniques, the collaboration seeks to bridge the gap between animal studies and human clinical trials, enabling a more efficient and accurate translation of promising therapeutics.Reykjavik, Iceland and Berlin, Germany  3Z, holds expertise in developing genetically engineered models of central nervous system disorders, has successfully identified potential ADHD

Zebrafish mutant model reveals novel drug candidates for ADHD

Reykjavik – 3Z. ADHD is a highly prevalent neurodevelopmental disorder. The first-line therapeutic for ADHD, methylphenidate, is beneficial for only a subset of patients and can cause side effects including weight loss, insomnia and hypertension. Therefore, the development of non-stimulant based therapeutics is of high importance. In a study published in the journal Neuropsychopharmacology 3Z scientists and collaborators used a uniquely powerful genetic model and unbiased drug screen to identify novel ADHD non-stimulant therapeutics. First, it was shown that when the human ADHD risk gene

3Z closes $2 million funding for preclinical development of novel ADHD and Insomnia therapeutics identified by 3Z´s zebrafish drug discovery platform.

Reykjavik – 3Z, a Reykjavik based drug discovery company is pleased to announce the closure of a $2 million funding round led by seasoned investors in pharmaceuticals and medical technology. The just closed funding will accelerate finalization of preclinical studies on 3Z´s lead therapeutic candidates in ADHD and insomnia. Using its unique zebrafish screening platform, 3Z has identified both novel and repurposed therapeutics for these indications; the platform allows for cost-effective high-volume screens in vivo.Currently, the lead therapeutics are being re-assayed in mammalian models,

There are no items matching the current filter
There are no more items matching the current filter
Back to top

Subscribe

Media